MIRUM PHARMACEUTICALS INC's ticker is MIRM and the CUSIP is 604749101. A total of 160 filers reported holding MIRUM PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 1.01 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $50,339 | +5.4% | 1,593 | -13.7% | 0.00% | 0.0% |
| Q2 2023 | $47,756 | +318273.3% | 1,846 | +186.6% | 0.00% | – |
| Q1 2023 | $15 | -66.7% | 644 | -72.3% | 0.00% | -100.0% |
| Q4 2022 | $45 | -99.9% | 2,329 | +5.4% | 0.00% | +100.0% |
| Q3 2022 | $46,000 | -16.4% | 2,210 | -21.2% | 0.00% | 0.0% |
| Q2 2022 | $55,000 | -56.0% | 2,803 | -50.6% | 0.00% | 0.0% |
| Q1 2022 | $125,000 | +92.3% | 5,679 | +39.6% | 0.00% | 0.0% |
| Q4 2021 | $65,000 | +441.7% | 4,068 | +599.0% | 0.00% | – |
| Q3 2021 | $12,000 | +9.1% | 582 | -9.8% | 0.00% | – |
| Q2 2021 | $11,000 | -15.4% | 645 | +1.3% | 0.00% | – |
| Q1 2021 | $13,000 | -86.6% | 637 | -88.5% | 0.00% | -100.0% |
| Q4 2020 | $97,000 | -23.0% | 5,557 | -15.0% | 0.00% | +200.0% |
| Q3 2020 | $126,000 | +447.8% | 6,536 | +463.4% | 0.00% | 0.0% |
| Q2 2020 | $23,000 | +155.6% | 1,160 | +30.9% | 0.00% | 0.0% |
| Q3 2019 | $9,000 | – | 886 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 6,470,392 | $204,464,387 | 13.58% |
| NEA Management Company, LLC | 2,186,243 | $69,085,279 | 5.34% |
| TANG CAPITAL MANAGEMENT LLC | 1,137,107 | $35,932,581 | 5.07% |
| BOONE CAPITAL MANAGEMENT LLC | 389,791 | $12,317,396 | 3.89% |
| Highlander Partners, L.P. | 122,980 | $3,886,168 | 3.84% |
| BVF INC/IL | 4,370,024 | $138,092,758 | 3.72% |
| Prosight Management, LP | 353,508 | $11,170,853 | 3.54% |
| Novo Holdings A/S | 1,500,000 | $47,400,000 | 3.50% |
| Nicholas Investment Partners, LP | 1,199,366 | $37,899,966 | 2.83% |
| Eventide Asset Management | 3,958,579 | $125,091,097 | 2.25% |